Lv75
4830 积分 2023-06-19 加入
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
29天前
已完结
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
1个月前
已完结
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
1个月前
已完结
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
2个月前
已完结
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
2个月前
已关闭
Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study
2个月前
已完结
Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair Deficient Locally Advanced Colon Cancer: An Emerging Strategy
2个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
2个月前
已完结
Nonoperative Management of Mismatch Repair–Deficient Tumors
2个月前
已完结
皖公网安备34019202002308
